{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:14Z","timestamp":1790668514478,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01285-0","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:46:46Z","timestamp":1788893206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding Nonlinearities in AAV-Based Gene Therapy Using PBPK Modelling"],"prefix":"10.1208","volume":"28","author":[{"given":"Aneesh","family":"Rajwade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokshada","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-6206","authenticated-orcid":false,"given":"Dhaval K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1285_CR1","unstructured":"What is the AAV Gene Therapy Market Size? : Precedence research; [Available from: https:\/\/www.precedenceresearch.com\/aav-gene-therapy-market. Accessed\u00a011\/1\/2025."},{"key":"1285_CR2","unstructured":"FDA approved drugs [Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed 11\/1\/2025."},{"key":"1285_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400521","author":"V Valayannopoulos","year":"2026","unstructured":"Valayannopoulos V, Bance M, Carvalho DS, Greinwald JH, Harvey SA, Ishiyama A, et al. DB-OTO gene therapy for inherited deafness. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2400521.","journal-title":"N Engl J Med"},{"issue":"5","key":"1285_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41434-025-00561-6","volume":"32","author":"K Chwalenia","year":"2025","unstructured":"Chwalenia K, Feng VY, Hemmer N, Friedrichsen HJ, Vorobieva I, Wood MJA, et al. AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects. Gene Ther. 2025;32(5):447\u201361.","journal-title":"Gene Ther"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","volume":"170","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury EA, Meno-Tetang G, Chang HY, Wu S, Huang HW, Jamier T, et al. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models. Adv Drug Deliv Rev. 2021;170:214\u201337.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"1285_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1208\/s12248-023-00867-6","volume":"25","author":"T Zhang","year":"2023","unstructured":"Zhang T, Zou P. Interspecies scaling of transgene products for viral vector gene therapies: method assessment using data from eleven viral vectors. AAPS J. 2023;25(6):101.","journal-title":"AAPS J"},{"issue":"3","key":"1285_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cpt.2269","volume":"110","author":"F Tang","year":"2021","unstructured":"Tang F, Wong H, Ng CM. Rational clinical dose selection of adeno-associated virus-mediated gene therapy based on allometric principles. Clin Pharmacol Ther. 2021;110(3):803\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1285_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1285_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.omtm.2022.10.011","volume":"27","author":"A Burr","year":"2022","unstructured":"Burr A, Erickson P, Bento R, Shama K, Roth C, Parekkadan B. Allometric-like scaling of AAV gene therapy for systemic protein delivery. Mol Ther Methods Clin Dev. 2022;27:368\u201379.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1285_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.xphs.2023.10.005","volume":"113","author":"S Liu","year":"2024","unstructured":"Liu S, Chowdhury EA, Xu V, Jerez A, Mahmood L, Ly BQ, et al. Whole-body disposition and physiologically based pharmacokinetic modeling of adeno-associated viruses and the transgene product. J Pharm Sci. 2024;113(1):141\u201357.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1285_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103601","volume":"392","author":"A Rajwade","year":"2025","unstructured":"Rajwade A, Liu S, Kumar M, Ghobrial A, Hahn S, Shah DK. Investigation of dose-exposure-response relationship for adeno-associated virus-mediated delivery of antibody genes. J Pharmacol Exp Ther. 2025;392(6):103601.","journal-title":"J Pharmacol Exp Ther"},{"key":"1285_CR12","unstructured":"Rohatgi A. WebPlotDigitizer (4.5). Computer software; 2021. Retrieved from: https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"1285_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-025-03918-z","author":"D Dou","year":"2025","unstructured":"Dou D, Lu J, Li D, He F, Zhu X, Zhang X, et al. Preclinical evaluation of AAV8-R338L gene therapy for hemophilia: efficacy, pharmacokinetics, distribution, excretion and toxicity in mouse models and non-human primates. Pharm Res. 2025. https:\/\/doi.org\/10.1007\/s11095-025-03918-z.","journal-title":"Pharm Res"},{"issue":"8","key":"1285_CR14","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1128\/JVI.02660-13","volume":"88","author":"SC Nicolson","year":"2014","unstructured":"Nicolson SC, Samulski RJ. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol. 2014;88(8):4132\u201344.","journal-title":"J Virol"},{"issue":"12","key":"1285_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","volume":"28","author":"JM Riyad","year":"2021","unstructured":"Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021;28(12):683\u201396.","journal-title":"Gene Ther"},{"issue":"11\u201312","key":"1285_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1089\/hum.2023.018","volume":"34","author":"C West","year":"2023","unstructured":"West C, Federspiel JD, Rogers K, Khatri A, Rao-Dayton S, Ocana MF, et al. Complement activation by adeno-associated virus-neutralizing antibody complexes. Hum Gene Ther. 2023;34(11\u201312):554\u201366.","journal-title":"Hum Gene Ther"},{"issue":"13","key":"1285_CR17","doi-asserted-by":"publisher","first-page":"7326","DOI":"10.1128\/JVI.00448-12","volume":"86","author":"CL Bell","year":"2012","unstructured":"Bell CL, Gurda BL, Van Vliet K, Agbandje-McKenna M, Wilson JM. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol. 2012;86(13):7326\u201333.","journal-title":"J Virol"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.omtm.2018.11.007","volume":"13","author":"P Guo","year":"2019","unstructured":"Guo P, Zhang J, Chrzanowski M, Huang J, Chew H, Firrman JA, et al. Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay. Mol Ther Methods Clin Dev. 2019;13:40\u20136.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"17","key":"1285_CR19","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1128\/JVI.00209-12","volume":"86","author":"C Raupp","year":"2012","unstructured":"Raupp C, Naumer M, M\u00fcller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt JA. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol. 2012;86(17):9396\u2013408.","journal-title":"J Virol"},{"issue":"15","key":"1285_CR20","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.1074\/jbc.M110.210922","volume":"286","author":"S Shen","year":"2011","unstructured":"Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal <em>N<\/em>-linked galactose is the primary receptor for adeno-associated virus 9 *. J Biol Chem. 2011;286(15):13532\u201340.","journal-title":"J Biol Chem"},{"issue":"2","key":"1285_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10928-014-9352-6","volume":"41","author":"JM Harrold","year":"2014","unstructured":"Harrold JM, Abraham AK. Ubiquity: a framework for physiological\/mechanism-based pharmacokinetic\/pharmacodynamic model development and deployment. J Pharmacokinet Pharmacodyn. 2014;41(2):141\u201351.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"1285_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF00285251","volume":"32","author":"CD Laird","year":"1971","unstructured":"Laird CD. Chromatid structure: relationship between DNA content and nucleotide sequence diversity. Chromosoma. 1971;32(4):378\u2013406.","journal-title":"Chromosoma"},{"issue":"8","key":"1285_CR23","doi-asserted-by":"publisher","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","volume":"14","author":"R Sender","year":"2016","unstructured":"Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016;14(8):e1002533.","journal-title":"PLoS Biol"},{"issue":"4","key":"1285_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/humc.2019.030","volume":"30","author":"T He","year":"2019","unstructured":"He T, Itano MS, Earley LF, Hall NE, Riddick N, Samulski RJ, et al. The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain. Hum Gene Ther Clin Dev. 2019;30(4):169\u201381.","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"1","key":"1285_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101434","volume":"33","author":"K Fang","year":"2025","unstructured":"Fang K, Yang X, Liu Y, Xia J, Wu R, Yang F, et al. A comprehensive study of AAV tropism across C57BL\/6 mice, BALB\/c mice, and crab-eating macaques. Mol Ther Methods Clin Dev. 2025;33(1):101434.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1285_CR26","unstructured":"FDA Investigating Deaths Due to Acute Liver Failure Following Treatment with Sarepta\u2019s AAVrh74 Gene Therapies [press release]. 2025."},{"issue":"13","key":"1285_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;389(13):1203\u201310.","journal-title":"N Engl J Med"},{"issue":"14","key":"1285_CR28","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","volume":"6","author":"J Guillou","year":"2022","unstructured":"Guillou J, de Pellegars A, Porcheret F, Fr\u00e9meaux-Bacchi V, Allain-Launay E, Debord C, et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 2022;6(14):4266\u201370.","journal-title":"Blood Adv"},{"issue":"6","key":"1285_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12586","volume":"5","author":"L Lisowski","year":"2021","unstructured":"Lisowski L, Staber JM, Wright JF, Valentino LA. The intersection of vector biology, gene therapy, and hemophilia. Res Pract Thromb Haemost. 2021;5(6):e12586.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"1285_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/bcp.15597","volume":"89","author":"P Zou","year":"2023","unstructured":"Zou P. Interspecies normalization of dose-response relationship for adeno-associated virus-mediated haemophilia gene therapy-Application to human dose prediction. Br J Clin Pharmacol. 2023;89(4):1393\u2013401.","journal-title":"Br J Clin Pharmacol"},{"issue":"7588","key":"1285_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, et al. An essential receptor for adeno-associated virus infection. Nature. 2016;530(7588):108\u201312.","journal-title":"Nature"},{"issue":"19","key":"1285_CR32","doi-asserted-by":"publisher","first-page":"9831","DOI":"10.1128\/JVI.00878-06","volume":"80","author":"B Akache","year":"2006","unstructured":"Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37\/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol. 2006;80(19):9831\u20136.","journal-title":"J Virol"},{"issue":"36","key":"1285_CR33","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1021\/bi4008676","volume":"52","author":"F Zhang","year":"2013","unstructured":"Zhang F, Aguilera J, Beaudet JM, Xie Q, Lerch TF, Davulcu O, et al. Characterization of interactions between heparin\/glycosaminoglycan and adeno-associated virus. Biochemistry. 2013;52(36):6275\u201385.","journal-title":"Biochemistry"},{"issue":"22","key":"1285_CR34","doi-asserted-by":"publisher","first-page":"12260","DOI":"10.1128\/JVI.01304-07","volume":"81","author":"HJ Nam","year":"2007","unstructured":"Nam HJ, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol. 2007;81(22):12260\u201371.","journal-title":"J Virol"},{"issue":"19","key":"1285_CR35","doi-asserted-by":"publisher","first-page":"10408","DOI":"10.1128\/JVI.01155-12","volume":"86","author":"S Shen","year":"2012","unstructured":"Shen S, Bryant KD, Sun J, Brown SM, Troupes A, Pulicherla N, et al. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol. 2012;86(19):10408\u201317.","journal-title":"J Virol"},{"issue":"20","key":"1285_CR36","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/sj.gt.3302564","volume":"12","author":"L Denby","year":"2005","unstructured":"Denby L, Nicklin SA, Baker AH. Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Ther. 2005;12(20):1534\u20138.","journal-title":"Gene Ther"},{"issue":"3","key":"1285_CR37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/gt.2012.41","volume":"20","author":"Y Liu","year":"2013","unstructured":"Liu Y, Joo KI, Wang P. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther. 2013;20(3):308\u201317.","journal-title":"Gene Ther"},{"issue":"3","key":"1285_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101326","volume":"32","author":"H Wang","year":"2024","unstructured":"Wang H, Li R, Sadekar S, Kamath AV, Shen BQ. A novel approach to quantitate biodistribution and transduction of adeno-associated virus gene therapy using radiolabeled AAV vectors in mice. Mol Ther Methods Clin Dev. 2024;32(3):101326.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1285_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton BA, Wright JF. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 2021;12:675897.","journal-title":"Front Immunol"},{"key":"1285_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666666","volume":"12","author":"HCJ Ertl","year":"2021","unstructured":"Ertl HCJ. T cell-mediated immune responses to AAV and AAV vectors. Front Immunol. 2021;12:666666.","journal-title":"Front Immunol"},{"issue":"3","key":"1285_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2025.101551","volume":"33","author":"R Xicluna","year":"2025","unstructured":"Xicluna R, Schwalie PC, Bell E, Von Tell D, Steiner G, Seeger E, et al. Innate immune response to AAV-based gene therapy vectors: mechanisms of complement activation and cytokine release. Mol Ther Methods Clin Dev. 2025;33(3):101551.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"42","key":"1285_CR42","doi-asserted-by":"publisher","first-page":"16754","DOI":"10.1073\/pnas.1310377110","volume":"110","author":"S Klumpp","year":"2013","unstructured":"Klumpp S, Scott M, Pedersen S, Hwa T. Molecular crowding limits translation and cell growth. Proc Natl Acad Sci U S A. 2013;110(42):16754\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1285_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","volume":"35","author":"SJ Bots","year":"2021","unstructured":"Bots SJ, Parker CE, Brandse JF, L\u00f6wenberg M, Feagan BG, Sandborn WJ, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35(6):715\u201333.","journal-title":"BioDrugs"},{"key":"1285_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13020299","author":"EL Howard","year":"2025","unstructured":"Howard EL, Goens MM, Susta L, Patel A, Wootton SK. Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13020299.","journal-title":"Biomedicines"},{"key":"1285_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471\u201394.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"677","key":"1285_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo1815","volume":"15","author":"SM Birch","year":"2023","unstructured":"Birch SM, Lawlor MW, Conlon TJ, Guo L-J, Crudele JM, Hawkins EC, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Sci Transl Med. 2023;15(677):eabo1815.","journal-title":"Sci Transl Med"},{"key":"1285_CR47","doi-asserted-by":"publisher","first-page":"16064","DOI":"10.1038\/mtm.2016.64","volume":"3","author":"AM Lange","year":"2016","unstructured":"Lange AM, Altynova ES, Nguyen GN, Sabatino DE. Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. Mol Ther - Methods Clin Dev. 2016;3:16064.","journal-title":"Mol Ther - Methods Clin Dev"},{"issue":"8","key":"1285_CR48","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","volume":"6","author":"TS Lundgren","year":"2022","unstructured":"Lundgren TS, Denning G, Stowell SR, Spencer HT, Doering CB. Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice. Blood Adv. 2022;6(8):2628\u201345.","journal-title":"Blood Adv"},{"issue":"6","key":"1285_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1208\/s12248-025-01155-1","volume":"27","author":"MA Tegenge","year":"2025","unstructured":"Tegenge MA, Yogurtcu ON, Belov AA, Wang X, Forshee RA. Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives. Aaps j. 2025;27(6):157.","journal-title":"Aaps j"},{"issue":"6","key":"1285_CR50","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3109\/03014460.2013.807878","volume":"40","author":"E Bianconi","year":"2013","unstructured":"Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40(6):463\u201371.","journal-title":"Ann Hum Biol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01285-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:27Z","timestamp":1790665347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01285-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"137"}}